Leman Biotech and the team led by professor Xingbing Wang, Director of the First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), reached a clinical trial cooperation agreement on "Clinical Trial Study on the Safety and Efficacy of Metabolism-enhanced CD19 CAR-T Cell Injection in the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma". The two parties have formally signed a cooperation agreement to establish a clinical project partnership and jointly promote multi-center IIT clinical research of metabolism-enhanced CAR-T cell therapy.
Non-Hodgkin's Lymphoma (NHL) is a common type of tumor, with Diffuse Large B-cell Lymphoma (DLBCL) being its most prevalent subtype, accounting for approximately 32.5% of new cases, and often more than 40% in Asian countries. Conventional CD19 CAR-T cell therapy, used as a second or third-line treatment, has a complete response rate (CR) of 40% to 50% for relapsed or refractory DLBCL, but almost half of the CR patients experience a relapse within a year. Thus, there is an urgent need to develop new CAR-T cell therapies to increase the CR rate of patients and reduce the rate of recurrence.
Based on the proprietary core technology of Meta 10 owned by Leman Biotech, the R&D team at Leman Biotech has developed the metabolism-enhanced CD19 CAR-T (Meta10-19 CAR-T), which has demonstrated impressive anti-tumor effects in multiple mouse tumor models. The therapy has the ability to produce a significant amount of immune memory cells to prevent tumor recurrence and may be a highly promising solution for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Professor Wang Xingbing is Chief Physician, Professor, Doctoral Supervisor, and Deputy Director of the Department of Hematology at the First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital). He is a member of several medical organizations, including the Hematology Branch of the Chinese Medical Association, the Flow Cytometry Group of the Hematology and Immunology Branch of the Chinese Society of Immunology, and the Anhui Hematological Oncology Branch of the Chinese Anti-Cancer Association. Additionally, he is a reviewer for scientific research funds and scientific and technological awards of the Ministry of Education, as well as a reviewer for SCI journals Clinical Immunology and Hematology. Professor Wang has received recognition for his contributions to the field, including awards such as the 15th Anhui Youth Science and Technology Award and the second prize of Anhui Province Science and Technology Progress Award. He is experienced in diagnosing and treating hematological diseases, with a focus on hematologic malignancies such as acute and chronic leukemia, malignant lymphoma, multiple myeloma, and myelodysplastic syndromes, and specializes in immune cell therapy and hematopoietic stem cell transplantation.
Leman Biotech is a clinical-staged cancer immunotherapy company co-founded by Professor Li Tang of the Swiss Federal Institute of Technology in Lausanne (EPFL) and AI-driven drug R&D leader XtalPi. The company combines innovative metabolic reprogramming technology with cutting-edge AI drug discovery platform to develop next-generation cancer immunotherapies. The core technology Meta 10 has the potential to cure solid tumors, as demonstrated in the published research in the top academic journal Nature Immunology, and has PCT patents in 56 countries and regions, covering major economies in the world. The company has a highly qualified R&D team, with over 70% of its personnel having graduated from esteemed Chinese and international universities and holding extensive industrial experience. Several of Leman Biotech's R&D pipelines are in advanced stage of development, including a metabolically armed CAR-T cell therapy in IIT clinical research stage. In December 2021, just half a year after its inception, Leman Biotech completed a successful angel round of financing, raising nearly $11 million, with plans for further financing underway. Leman Biotech is committed to finding solutions to the bottlenecks in cancer immunotherapy, improving the response rate and efficacy, and making unremitting efforts to achieve the ultimate goal of curing cancer.
